<?xml version="1.0" encoding="UTF-8"?>
<p>Piperaquine was developed in the 1960s and used in China and India for several years as a replacement for chloroquine, which is structurally similar. Both drugs are thought to accumulate in the digestive vacuole of the parasite and to interfere with the detoxification of heme. Resistance to piperaquine quickly evolved in nature, and the drug fell out of use as a monotherapy, and was later adopted for use in combination with artemisinin (
 <xref rid="B27" ref-type="bibr">Davis et al., 2005</xref>). Resistance to this combination has recently emerged in western Cambodia, where over 40% of combination treatments fail to eliminate parasites from patientsâ€™ blood (
 <xref rid="B35" ref-type="bibr">Duru et al., 2016</xref>); however, the mechanisms by which parasites become resistant to piperaquine remain unclear (
 <xref rid="B50" ref-type="bibr">Haldar et al., 2018</xref>).
</p>
